ChemicalBook >> CAS DataBase List >>PF-01367338

PF-01367338

CAS No.
459868-92-9
Chemical Name:
PF-01367338
Synonyms
CS-47;AG14699;Rubraca;AG-014699;PF-01367338;Rucaparib(AG-01);Rucaparib D4 HCl;AG014699 phosphate;Rucaparib phosphate;PF-01367338/AG14699
CBNumber:
CB82515928
Molecular Formula:
C19H21FN3O5P
Molecular Weight:
421.37
MDL Number:
MFCD17010269
MOL File:
459868-92-9.mol
MSDS File:
SDS
Last updated:2025-04-17 18:22:24

PF-01367338 Properties

Melting point >173°C (dec.)
storage temp. Sealed in dry,Room Temperature
solubility Soluble in DMSO (up to 25 mg/ml).
form Yellow solid.
color Yellow
Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
FDA UNII H3M9955244
NCI Dictionary of Cancer Terms AG014699
NCI Drug Dictionary Rubraca

SAFETY

Risk and Safety Statements

PF-01367338 price More Price(44)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 11570 Rucaparib (phosphate) ≥98% 459868-92-9 1mg $32 2024-03-01 Buy
Cayman Chemical 11570 Rucaparib (phosphate) ≥98% 459868-92-9 5mg $139 2024-03-01 Buy
Cayman Chemical 11570 Rucaparib (phosphate) ≥98% 459868-92-9 10mg $243 2024-03-01 Buy
TRC A425500 AG14699 459868-92-9 10mg $140 2021-12-16 Buy
TRC A425500 AG14699 459868-92-9 5mg $90 2021-12-16 Buy
Product number Packaging Price Buy
11570 1mg $32 Buy
11570 5mg $139 Buy
11570 10mg $243 Buy
A425500 10mg $140 Buy
A425500 5mg $90 Buy

PF-01367338 Chemical Properties,Uses,Production

Description

Rucaparib phosphate (459868-92-9) is a potent (Ki<5 nM) PARP1 inhibitor.1?Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2.2?Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines.3?Synergizes with other anticancer agents such as topotecan, carboplatin, doxorubicin, paclitaxel,3 and temozolomide.4?Ameliorates the cardiotoxicity of doxorubicin.5?Recently approved for human use by the FDA.

Uses

PARP inhibitor oncolytic

in vivo

Rucaparib (AG014699) phosphate and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) phosphate significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) phosphate results in a 50% increase in the temozolomide-induced tumor growth delay[1].
Rucaparib (10 mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) phosphate significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions[2].
Rucaparib (150 mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) phosphate has greatest antitumor effect with three complete regressions[2].
Rucaparib phosphate enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts[6].

Animal Model:Female athymic nude mice, implanted SW620 colorectal tumor cells (1 × 107 cells per animal) s.c.[1]
Dosage:0.1 mg/kg in combination with Temozolomide (p.o., 200 mg/kg), 0.05, 0.15, and 0.5 mg/kg in combination with Temozolomide (p.o., 68 mg/kg) or 10 mg/kg
Administration:IP, single dose for 0.1 mg/kg and 10 mg/kg, five daily doses for 0-0.5 mg/kg
Result:Significantly increased Temozolomide toxicity, showed outstanding chemosensitization potency and caused enhancement of Temozolomide-induced tumor growth delay
Animal Model:CD-1 nude mice bearing established Capan-1 xenografts[2]
Dosage:10 mg/kg or 50, 100 and 150?mg/kg
Administration:IP for 10 mg/kg; PO for 50, 100 and 150?mg/kg, single dose (Pharmacokinetics)
Result:Parent drug was detectable in the plasma only at 30?min after 10?mg/kg i.p and up to 4?h for 50–150?mg/kg p.o.. Was still detectable in most mice receiving oral rucaparib at 3 days. Does not easily cross the plasma membrane.
Animal Model:CD-1 nude mice bearing established Capan-1 xenografts[2]
Dosage:10?mg/kg i.p. daily for 5 days per week for 6 weeks, 50 or 150?mg/kg p.o. daily × five weekly × six, 150?mg/kg p.o. once per week for 6 weeks or three times per week for 6 weeks, or 150?mg/kg p.o. daily for five days every 3 weeks
Administration:IP or PO
Result:10?mg/kg i.p. significantly inhibited the growth of the tumor, daily oral administration at 150?mg/kg had an equivalent effect on tumor growth to 10?mg/kg i.p.. The schedule with the greatest antitumor effect was oral administration of 150?mg/kg on a once weekly schedule with three complete regressions.
Animal Model:CD-1 nude mice, NB1691 and SHSY5Y xenografts[6]
Dosage:1 mg/kg
Administration:IP, daily for 5 d in combination with Temozolomide (orally daily ×5 at a dose of 68 mg/kg)
Result:Enhanced the antitumor activity of Temozolomide and indicated complete and sustained tumor regression.

IC 50

PARP-1: 1.4 nM (Ki); PARP-2; PARP-3

References

1) Thomas?et al.?(2007),?Preclinical selection of a n novel poly(ADP-ribose) polymerase inhibitor for clinical trial; Mol. Cancer Ther.,?6?945 2) Drew?et al.?(2011),?Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2; J. Natl. Cancer Inst.,?103?334 3) Ihnen?et al.?(2013),?Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer; Mol. Cancer Ther.,?12?1002 4) Plummer?et al.?(2013),?A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation; Cancer Chemother. Pharmacol.,?71?1191 5) Ali?et al.?(2011),?The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice; Mol. Cancer Ther.,?10?2320

PF-01367338 Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 221)Suppliers
Supplier Tel Email Country ProdList Advantage
Hebei Mujin Biotechnology Co.,Ltd
+86 13288715578 +8613288715578 sales@hbmojin.com China 12776 58
Capot Chemical Co.,Ltd.
+86-(0)57185586718 +86-13336195806 sales@capot.com China 29730 60
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21626 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 33024 60
Anqing Chico Pharmaceutical Co., Ltd.
15380796838 chloewu@chicopharm.cn CHINA 340 58
career henan chemical co
+86-0371-86658258 +8613203830695 sales@coreychem.com China 29856 58
Zhejiang ZETian Fine Chemicals Co. LTD
+8618957127338 stella@zetchem.com China 2136 58
Biochempartner
0086-13720134139 candy@biochempartner.com CHINA 965 58
Hangzhou Cyanochem Co., Ltd.
+86 17788583750 sales@cyanochem.com CHINA 281 58
Shenzhen Excellent Biotech Co., Ltd.
13480692018 ramyan@ex-biotech.com CHINA 954 58

View Lastest Price from PF-01367338 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Rucaparib pictures 2025-05-23 Rucaparib
459868-92-9
US $0.00-0.00 / KG 1KG 99% 500000kg Hebei Chuanghai Biotechnology Co., Ltd
PF-01367338 pictures 2025-05-16 PF-01367338
459868-92-9
US $0.00 / KG 1KG 99% 50000KG/month Hebei Mujin Biotechnology Co.,Ltd
 Rucaparib phosphate;PF01367338 phosphate pictures 2025-04-04 Rucaparib phosphate;PF01367338 phosphate
459868-92-9
US $0.00-0.00 / kg 1kg 98% 1Ton Henan Aochuang Chemical Co.,Ltd.
  • Rucaparib pictures
  • Rucaparib
    459868-92-9
  • US $0.00-0.00 / KG
  • 99%
  • Hebei Chuanghai Biotechnology Co., Ltd
  • PF-01367338 pictures
  • PF-01367338
    459868-92-9
  • US $0.00 / KG
  • 99%
  • Hebei Mujin Biotechnology Co.,Ltd

PF-01367338 Spectrum

AG-014699 AG-014699;PF-01367338 PF-01367338 AG14699 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one phosphate Rucaparib (AG-014699 , PF-01367338) Rucaparib phosphate AG-014699 (Rucaparib) 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(MethylaMino)Methyl]phenyl]-, phosphate (1:1) PF-01367338/AG14699 Rucaparib(AG-014699) 8-fluoro-5-(4-((methylamino)methyl)phenyl)-3,4-dihydro-2H-azepino[5,4,3-cd]indol-1(6H)-one phosphoric acid 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one phosphate Rucaparib(AG-014699) AG 014699 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one phosphate Rucaparib ( PF-01367338) Rucaparib phosphate AG-014699 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one phosphate Rucaparib(AG-01) 8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-onephosphate 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one pho PF01367338 phosphate Rucaparib (AG-014699,PF-01367338) phosphate Rucaparib (AG-014699) phosphate AG014699;RUCAPARIB PHOSPHATE Rucaparib (phosphate)(AG-014699,PF-01367338) Rucaparib phosphate salt Rucaparib phosphate (AG-14699, PF-01367338) CS-47 AG 014699 - PF 01367338 | Rucaparib AG-014447 (as free base) AG-14699 (as phosphate salt) AG-14699 (AS PHOSPHATE SALT); AG-014447 (AS FREE BASE); RUCAPARIB; PF-01367338; AG014699; AG 014699 phosphate AG014699 phosphate AG-014699 phosphate RUCAPARIB PHOSPHATE;AG014699 PHOSPHATE;PF01367338 PHOSPHATE;AG 014699 PHOSPHATE;PF 01367338 PHOSPHATE;AG-014699 PHOSPHATE;PF-01367338 PHOSPHATE AG14699 (AS PHOSPHATE SALT); AG 14699; AG-14699; AG014447 (AS FREE BASE); AG-014447; AG 014447; PF01367338; PF-01367338; PF 01367338; RUCAPARIB; RUBRACA; Rubraca PF-01367338 USP/EP/BP Rucaparib D4 HCl TIANFUCHEM--PF-01367338 Rucaparib Phosphate, 10 mM in DMSO 459868-92-9 C19H21FN3O5P C19H18FN3OH3PO4 C19H18FN3OH3O4P Inhibitors Inhibitor Amines Aromatics Heterocycles Intermediates & Fine Chemicals Pharmaceuticals